AR077820A1 - Inhibidores de las jnk - Google Patents
Inhibidores de las jnkInfo
- Publication number
- AR077820A1 AR077820A1 ARP100102908A ARP100102908A AR077820A1 AR 077820 A1 AR077820 A1 AR 077820A1 AR P100102908 A ARP100102908 A AR P100102908A AR P100102908 A ARP100102908 A AR P100102908A AR 077820 A1 AR077820 A1 AR 077820A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- alkyl
- haloalkyl
- lower alkyl
- alkoxy
- Prior art date
Links
- 239000012825 JNK inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000001188 haloalkyl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- -1 cyano, amino Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23252209P | 2009-08-10 | 2009-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077820A1 true AR077820A1 (es) | 2011-09-28 |
Family
ID=42710723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102908A AR077820A1 (es) | 2009-08-10 | 2010-08-09 | Inhibidores de las jnk |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8536172B2 (https=) |
| EP (1) | EP2464640A1 (https=) |
| JP (1) | JP5784604B2 (https=) |
| KR (1) | KR101506318B1 (https=) |
| CN (1) | CN102471319B (https=) |
| AR (1) | AR077820A1 (https=) |
| AU (1) | AU2010283769B2 (https=) |
| BR (1) | BR112012003059A2 (https=) |
| CA (1) | CA2768749A1 (https=) |
| IL (1) | IL217756A0 (https=) |
| IN (1) | IN2012DN01231A (https=) |
| MX (1) | MX2012001449A (https=) |
| SG (1) | SG178321A1 (https=) |
| TW (1) | TW201109336A (https=) |
| WO (1) | WO2011018417A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012030814A2 (pt) * | 2010-06-04 | 2019-09-24 | Hoffmann La Roche | inibidores de jnk |
| US9062026B2 (en) * | 2012-07-20 | 2015-06-23 | Cleave Biosciences, Inc. | Fused pyrimidines and substituted quinazolines as inhibitors of p97 |
| ES2870085T3 (es) * | 2013-06-26 | 2021-10-26 | Xigen Inflammation Ltd | Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2066319B1 (en) * | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| CN101547917A (zh) * | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 用作jnk调节剂的取代的嘧啶类化合物及它们的应用 |
-
2010
- 2010-08-06 SG SG2012008819A patent/SG178321A1/en unknown
- 2010-08-06 AU AU2010283769A patent/AU2010283769B2/en not_active Ceased
- 2010-08-06 WO PCT/EP2010/061476 patent/WO2011018417A1/en not_active Ceased
- 2010-08-06 CN CN201080035300.3A patent/CN102471319B/zh not_active Expired - Fee Related
- 2010-08-06 EP EP10739948A patent/EP2464640A1/en not_active Withdrawn
- 2010-08-06 IN IN1231DEN2012 patent/IN2012DN01231A/en unknown
- 2010-08-06 JP JP2012524207A patent/JP5784604B2/ja not_active Expired - Fee Related
- 2010-08-06 MX MX2012001449A patent/MX2012001449A/es active IP Right Grant
- 2010-08-06 KR KR1020127006275A patent/KR101506318B1/ko not_active Expired - Fee Related
- 2010-08-06 CA CA2768749A patent/CA2768749A1/en not_active Abandoned
- 2010-08-06 BR BR112012003059A patent/BR112012003059A2/pt not_active IP Right Cessation
- 2010-08-09 TW TW099126517A patent/TW201109336A/zh unknown
- 2010-08-09 AR ARP100102908A patent/AR077820A1/es unknown
- 2010-08-09 US US12/852,540 patent/US8536172B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 IL IL217756A patent/IL217756A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201109336A (en) | 2011-03-16 |
| AU2010283769A1 (en) | 2012-02-09 |
| CN102471319B (zh) | 2014-06-18 |
| SG178321A1 (en) | 2012-03-29 |
| MX2012001449A (es) | 2012-03-26 |
| US8536172B2 (en) | 2013-09-17 |
| CN102471319A (zh) | 2012-05-23 |
| WO2011018417A1 (en) | 2011-02-17 |
| IN2012DN01231A (https=) | 2015-05-15 |
| EP2464640A1 (en) | 2012-06-20 |
| BR112012003059A2 (pt) | 2016-08-02 |
| CA2768749A1 (en) | 2011-02-17 |
| US20110034470A1 (en) | 2011-02-10 |
| IL217756A0 (en) | 2012-03-29 |
| KR101506318B1 (ko) | 2015-03-26 |
| JP2013501746A (ja) | 2013-01-17 |
| AU2010283769B2 (en) | 2015-09-17 |
| JP5784604B2 (ja) | 2015-09-24 |
| KR20120055645A (ko) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| MX2012003499A (es) | Inhibidores de demetilasa-1 especificos de lisina y su uso. | |
| UA117151C2 (uk) | N-ациліміногетероциклічні сполуки | |
| EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| AR077820A1 (es) | Inhibidores de las jnk | |
| UA108510C2 (xx) | Циклопропанова сполука | |
| UA100003C2 (ru) | Соединения 1,2,4,5-тетрагидро-3н-бензазепина, способ их получения и фармацевтическая композиция, которая их содержит | |
| EA201200189A1 (ru) | Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| CO6801736A2 (es) | Derivados heterocíclicos de amina | |
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| DK2125736T3 (da) | Substituerede acetophenoner egnede som PDE4-inhibitorer | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| ECSP14013296A (es) | Derivados de etinilo | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |